1. Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection
Jean-Jacques Patard 
European Urology Supplements 
Volume 7, Issue 9, Pages (September 2008)
DOI: /j.eursup
Copyright © 2008 European Association of Urology Terms and Conditions

2. Fig. 1
Progression-free survival (PFS) by Memorial Sloan-Kettering Cancer Center risk group in patients treated with sunitinib or interferon-α in the first-line setting.
European Urology Supplements 2008 7, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions

3. Fig. 2
Progression-free survival (PFS) by Memorial Sloan-Kettering Cancer Center risk group in patients previously treated with cytokines in the sunitinib expanded-access study.
European Urology Supplements 2008 7, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions

4. Fig. 3
Progression-free survival (PFS) in sunitinib-treated patients according to the risk factors derived from a multivariate analysis (phase 3 trial comparing sunitinib to interferon-α).
European Urology Supplements 2008 7, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions

5. Fig. 4
Progression-free survival (PFS) in subgroups of patients previously treated with cytokines in the expanded-access study.
European Urology Supplements 2008 7, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions

6. Fig. 5 Treatment algorithm for metastatic renal cell carcinoma.
IFN-α, interferon-α; IL-2, interleukin 2; mRCC, metastatic renal cell carcinoma; MSKCC, Memorial Sloan-Kettering Cancer Center; mTOR, mammalian target of rapamycin.
European Urology Supplements 2008 7, DOI: ( /j.eursup )
Copyright © 2008 European Association of Urology Terms and Conditions